Literature DB >> 27836988

Sphingomyelinase-like phosphodiesterase 3b mediates radiation-induced damage of renal podocytes.

Anis Ahmad1, Alla Mitrofanova2,3,4, Jacek Bielawski5, Yidong Yang1, Brian Marples1, Alessia Fornoni2,4,6, Youssef H Zeidan7,8.   

Abstract

The molecular mechanisms responsible for the development of proteinuria and glomerulosclerosis in radiation nephropathy remain largely unknown. Podocytes are increasingly recognized as key players in the pathogenesis of proteinuria in primary and secondary glomerular disorders. The lipid-modulating enzyme sphingomyelin phosphodiesterase acid-like 3B (SMPDL3b) is a key determinant of podocyte injury and a known off target of the anti-CD20 antibody rituximab (RTX). The current study investigates the role of sphingolipids in radiation-induced podocytopathy. After a single dose of radiation (8 Gy), several ceramide species were significantly elevated. In particular, C16:00, C24:00, and C24:1 ceramides were the most abundant ceramide species detected. These changes were paralleled by a time-dependent drop in SMPDL3b protein, sphingosine, and sphingosine-1-phosphate levels. Interestingly, SMPDL3b-overexpressing podocytes had higher basal levels of sphingosine-1-phosphate and maintained basal ceramide levels after irradiation. Morphologically, irradiated podocytes demonstrated loss of filopodia and remodeling of cortical actin. Furthermore, the actin binding protein ezrin relocated from the plasma membrane to the cytosol as early as 2 h after radiation. In contrast, SMPDL3b overexpressing podocytes were protected from radiation-induced cytoskeletal remodeling. Treatment with RTX before radiation exposure partially protected podocytes from SMPDL3b loss, cytoskeletal remodeling, and caspase 3 cleavage. Our results demonstrate that radiation injury induces early cytoskeletal remodeling, down-regulation of SMPDL3b, and elevation of cellular ceramide levels. Overexpression of SMPDL3b and pretreatment with RTX confer a radioprotective effect in cultured podocytes. These findings indicate a potential role for SMPDL3b and RTX in radiation-induced podocytopathy.-Ahmad, A., Mitrofanova, A., Bielawski, J., Yang, Y., Marples, B., Fornoni, A., Zeidan, Y. H. Sphingomyelinase-like phosphodiesterase 3b mediates radiation-induced damage of renal podocytes. © FASEB.

Entities:  

Keywords:  cancer; ceramide; lipids; radioprotection

Mesh:

Substances:

Year:  2016        PMID: 27836988      PMCID: PMC6137603          DOI: 10.1096/fj.201600618R

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  35 in total

1.  Radiation nephritis. A long-term study of 54 patients.

Authors:  R W LUXTON
Journal:  Lancet       Date:  1961-12-02       Impact factor: 79.321

2.  Simultaneous quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry.

Authors:  Jacek Bielawski; Zdzislaw M Szulc; Yusuf A Hannun; Alicja Bielawska
Journal:  Methods       Date:  2006-06       Impact factor: 3.608

Review 3.  The acid sphingomyelinase/ceramide pathway: biomedical significance and mechanisms of regulation.

Authors:  Y H Zeidan; Y A Hannun
Journal:  Curr Mol Med       Date:  2010-07       Impact factor: 2.222

4.  Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor.

Authors:  Federico Perosa; Elvira Favoino; Maria Antonietta Caragnano; Franco Dammacco
Journal:  Blood       Date:  2005-10-13       Impact factor: 22.113

Review 5.  Renal complications of Fabry disease.

Authors:  Nikolina Basic-Jukic; Petar Kes; Marijana Coric; Vanja Basic-Kes
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

6.  Bimodal effect of advanced glycation end products on mesangial cell proliferation is mediated by neutral ceramidase regulation and endogenous sphingolipids.

Authors:  Karen Geoffroy; Nicolas Wiernsperger; Michel Lagarde; Samer El Bawab
Journal:  J Biol Chem       Date:  2004-06-07       Impact factor: 5.157

7.  Cisplatin-induced CD95 redistribution into membrane lipid rafts of HT29 human colon cancer cells.

Authors:  Sandrine Lacour; Arlette Hammann; Solène Grazide; Dominique Lagadic-Gossmann; Anne Athias; Odile Sergent; Guy Laurent; Philippe Gambert; Eric Solary; Marie-Thérèse Dimanche-Boitrel
Journal:  Cancer Res       Date:  2004-05-15       Impact factor: 12.701

8.  Saturated fatty acids induce insulin resistance in human podocytes: implications for diabetic nephropathy.

Authors:  Rachel Lennon; Deborah Pons; Matthew A Sabin; Christina Wei; Julian P Shield; Richard J Coward; Jeremy M Tavaré; Peter W Mathieson; Moin A Saleem; Gavin I Welsh
Journal:  Nephrol Dial Transplant       Date:  2009-06-25       Impact factor: 5.992

Review 9.  Podocyte pathology and nephropathy - sphingolipids in glomerular diseases.

Authors:  Sandra Merscher; Alessia Fornoni
Journal:  Front Endocrinol (Lausanne)       Date:  2014-07-30       Impact factor: 5.555

10.  Remodeling of cellular cytoskeleton by the acid sphingomyelinase/ceramide pathway.

Authors:  Youssef H Zeidan; Russell W Jenkins; Yusuf A Hannun
Journal:  J Cell Biol       Date:  2008-04-21       Impact factor: 10.539

View more
  15 in total

Review 1.  Immunopathogenesis of idiopathic nephrotic syndrome in children: two sides of the coin.

Authors:  Jing Chen; Xiao-Hui Qiao; Jian-Hua Mao
Journal:  World J Pediatr       Date:  2021-03-03       Impact factor: 2.764

2.  Effect of a bradykinin-potentiating factor isolated from scorpion venom (Leiurus quinquestriatus) on some blood indices and lipid profile in irradiated rats.

Authors:  Muhammad M A Salman; Ahmed M Kotb; Mohie A M Haridy; Klaus Golka; Seddik Hammad
Journal:  Mol Cell Biochem       Date:  2017-04-08       Impact factor: 3.396

3.  Sphingomyelin Phosphodiesterase Acid-Like 3b is Essential for Toll-Like Receptor 3 Signaling in Human Podocytes.

Authors:  Shojiro Watanabe; Umetsu Hidenori; Shun Hashimoto; Sato Riko; Tomomi Aizawa; Koji Tsugawa; Tadaatsu Imaizumi; Hiroshi Tanaka
Journal:  J Membr Biol       Date:  2021-11-05       Impact factor: 1.843

4.  Noninvasive assessment of radiation-induced renal injury in mice.

Authors:  Anis Ahmad; Junwei Shi; Saba Ansari; Jumana Afaghani; Judith Molina; Alan Pollack; Sandra Merscher; Youssef H Zeidan; Alessia Fornoni; Brian Marples
Journal:  Int J Radiat Biol       Date:  2021-03-15       Impact factor: 2.694

Review 5.  Sphingosine-1-Phosphate Metabolism and Signaling in Kidney Diseases.

Authors:  Yelena Drexler; Judith Molina; Alla Mitrofanova; Alessia Fornoni; Sandra Merscher
Journal:  J Am Soc Nephrol       Date:  2020-12-18       Impact factor: 14.978

Review 6.  Translational Aspects of Sphingolipid Metabolism in Renal Disorders.

Authors:  Alaa Abou Daher; Tatiana El Jalkh; Assaad A Eid; Alessia Fornoni; Brian Marples; Youssef H Zeidan
Journal:  Int J Mol Sci       Date:  2017-11-25       Impact factor: 5.923

Review 7.  Modulation of DNA Damage Response by Sphingolipid Signaling: An Interplay that Shapes Cell Fate.

Authors:  Marina Francis; Alaa Abou Daher; Patrick Azzam; Manal Mroueh; Youssef H Zeidan
Journal:  Int J Mol Sci       Date:  2020-06-24       Impact factor: 5.923

8.  Phosphodiesterase SMPDL3B Gene Expression as Independent Outcome Prediction Marker in Localized Prostate Cancer.

Authors:  Frank Waldbillig; Katja Nitschke; Abdallah Abdelhadi; Jost von Hardenberg; Philipp Nuhn; Malin Nientiedt; Cleo-Aron Weis; Maurice Stephan Michel; Philipp Erben; Thomas Stefan Worst
Journal:  Int J Mol Sci       Date:  2020-06-19       Impact factor: 5.923

Review 9.  Crosstalk Between Lipids and Mitochondria in Diabetic Kidney Disease.

Authors:  G Michelle Ducasa; Alla Mitrofanova; Alessia Fornoni
Journal:  Curr Diab Rep       Date:  2019-11-21       Impact factor: 5.430

Review 10.  Lipid mediators of insulin signaling in diabetic kidney disease.

Authors:  Alla Mitrofanova; Marie Anne Sosa; Alessia Fornoni
Journal:  Am J Physiol Renal Physiol       Date:  2019-09-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.